ES2598277T3 - Hidralazina para su uso en el tratamiento de la degeneración macular asociada a la edad - Google Patents

Hidralazina para su uso en el tratamiento de la degeneración macular asociada a la edad Download PDF

Info

Publication number
ES2598277T3
ES2598277T3 ES12173008.9T ES12173008T ES2598277T3 ES 2598277 T3 ES2598277 T3 ES 2598277T3 ES 12173008 T ES12173008 T ES 12173008T ES 2598277 T3 ES2598277 T3 ES 2598277T3
Authority
ES
Spain
Prior art keywords
compound
macular degeneration
administration
subject
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES12173008.9T
Other languages
English (en)
Spanish (es)
Inventor
George C. Chiou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
Original Assignee
Texas A&M University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System filed Critical Texas A&M University System
Application granted granted Critical
Publication of ES2598277T3 publication Critical patent/ES2598277T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES12173008.9T 2005-05-12 2006-05-04 Hidralazina para su uso en el tratamiento de la degeneración macular asociada a la edad Expired - Lifetime ES2598277T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US68099805P 2005-05-12 2005-05-12
US680998P 2005-05-12
US77642606P 2006-02-24 2006-02-24
US776426P 2006-02-24
US11/416,773 US8088773B2 (en) 2005-05-12 2006-05-03 Therapeutic compositions and methods
US416773 2006-05-03

Publications (1)

Publication Number Publication Date
ES2598277T3 true ES2598277T3 (es) 2017-01-26

Family

ID=37431545

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12173008.9T Expired - Lifetime ES2598277T3 (es) 2005-05-12 2006-05-04 Hidralazina para su uso en el tratamiento de la degeneración macular asociada a la edad

Country Status (9)

Country Link
US (5) US8088773B2 (https=)
EP (3) EP1885371A4 (https=)
JP (2) JP5335419B2 (https=)
AU (1) AU2006247892B2 (https=)
CA (1) CA2608163C (https=)
DE (1) DE202006020318U1 (https=)
ES (1) ES2598277T3 (https=)
PL (1) PL2508182T3 (https=)
WO (1) WO2006124324A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110079922A (ko) * 2006-04-14 2011-07-11 노파르티스 아게 안과 장애 치료를 위한 ｉｌ－1 항체의 용도
US7736860B2 (en) * 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
GB0625270D0 (en) * 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
ES2964555T3 (es) 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
WO2013188217A1 (en) 2012-06-11 2013-12-19 Macuclear, Inc. Therapeutic formulation and methods of treatment
EP2895168A4 (en) * 2012-09-13 2016-08-31 Cba Pharma Inc TETRANDRINE MEDICINAL FORMULATIONS AND METHOD
WO2015012210A1 (ja) 2013-07-23 2015-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ縮合環化合物
US9370503B1 (en) * 2015-02-26 2016-06-21 Chi Chou Liao Compounds for treating ocular diseases
BR112020011625A2 (pt) 2017-12-11 2020-11-17 Artelo Biosciences, Inc. formas sólidas de canabidiol e usos das mesmas
US10632211B2 (en) * 2018-06-11 2020-04-28 The Regents Of The University Of California Demethylation to treat eye disease
CN110585196B (zh) * 2018-06-13 2022-11-04 郭涛 一种治疗及预防眼科疾病的药物及其应用
CN112007031A (zh) * 2019-05-30 2020-12-01 杏国新药股份有限公司 眼用制剂
EP3949958A1 (en) * 2020-08-04 2022-02-09 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound for the treatment and prophylaxis of a lipofuscin-associated disease
CN114276251B (zh) * 2021-12-07 2022-12-16 武汉大学 一种合成硝基(杂)芳烃的方法
US20240285572A1 (en) * 2023-02-27 2024-08-29 Opticgon Llc Compositions comprising nitric oxide-releasing compounds for treating choroidal vascular diseases and methods of their use

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055645A (en) * 1976-02-13 1977-10-25 Merck & Co., Inc. Novel anti-hypertensive compositions
FI873429A7 (fi) * 1986-08-18 1988-02-19 Houston Biotechnology Incorporated Silmälääketieteelliset koostumukset hermodegeneraatioiden hoitoon.
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
IT1201151B (it) 1987-01-14 1989-01-27 Indena Spa Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono
US5500230A (en) * 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5194434A (en) * 1991-12-03 1993-03-16 Texas A&M University System Use of OB-101 to treat ocular inflammation
US5252607A (en) 1992-01-24 1993-10-12 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5422166A (en) * 1993-02-12 1995-06-06 Wangner Systems Corporation Abrasion resisting edge for a forming fabric
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5596011A (en) 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
CA2252962A1 (en) 1996-04-26 1997-11-06 Fujisawa Pharmaceutical Co., Ltd. Peripheral circulation improvers for ophthalmic tissues containing dihydropyridines
WO1998010758A1 (en) * 1996-09-13 1998-03-19 The Regents Of The University Of California Methods for treatment of retinal diseases
JP4828670B2 (ja) 1996-10-28 2011-11-30 千寿製薬株式会社 眼循環障害改善剤
WO1999044603A1 (en) 1998-03-06 1999-09-10 Sponsel William E Composition and method for treating macular disorders
US6028099A (en) 1998-03-13 2000-02-22 John Hopkins University, School Of Medicine Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization
WO2000000194A1 (en) * 1998-06-27 2000-01-06 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
EP1161686A2 (en) * 1999-03-05 2001-12-12 University Of Iowa Research Foundation Diagnostics and therapeutics for drusen associated ocular disorders
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
AU779991B2 (en) * 1999-08-10 2005-02-24 Board Of Regents, The University Of Texas System Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
JP4372905B2 (ja) * 1999-09-02 2009-11-25 興和株式会社 網膜神経細胞保護剤
US20030007971A1 (en) * 2000-01-31 2003-01-09 Hideaki Hara Remedies for ophthalmic diseases
EP1712239A3 (en) * 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US6692759B1 (en) * 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
US20030171375A1 (en) * 2002-02-13 2003-09-11 Brazzell Romulus Kimbro Method for treating ocular neovascular diseases
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
AU2003287250B9 (en) * 2002-10-30 2010-01-28 Ptc Therapeutics, Inc. Identifying therapeutic compounds based on their physical-chemical properties
JP2004250347A (ja) * 2003-02-18 2004-09-09 Ajinomoto Co Inc 網膜虚血に基づく疾患の治療および／又は予防剤
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
CA2576279A1 (en) * 2004-11-08 2006-05-18 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders

Also Published As

Publication number Publication date
CA2608163C (en) 2011-10-25
US8088773B2 (en) 2012-01-03
AU2006247892B2 (en) 2010-04-22
WO2006124324A1 (en) 2006-11-23
US8318741B2 (en) 2012-11-27
JP2012229257A (ja) 2012-11-22
JP5335419B2 (ja) 2013-11-06
EP2508182B1 (en) 2016-07-06
AU2006247892A1 (en) 2006-11-23
EP1885371A1 (en) 2008-02-13
EP1885371A4 (en) 2010-04-07
US20130059841A1 (en) 2013-03-07
US20120115959A1 (en) 2012-05-10
EP2508183A1 (en) 2012-10-10
CA2608163A1 (en) 2006-11-23
US20120071485A1 (en) 2012-03-22
PL2508182T3 (pl) 2017-05-31
DE202006020318U1 (de) 2008-07-31
JP5643263B2 (ja) 2014-12-17
EP2508183B1 (en) 2014-07-09
US20120196868A1 (en) 2012-08-02
HK1177419A1 (en) 2013-08-23
EP2508182A1 (en) 2012-10-10
JP2008540528A (ja) 2008-11-20
US20060276458A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
ES2598277T3 (es) Hidralazina para su uso en el tratamiento de la degeneración macular asociada a la edad
ES2935605T3 (es) Combinaciones de cannabinoides y N-aciletanolaminas
ES2257768T3 (es) Antagonistas de neurotropina para el tratamiento de epilepsia, enfermedad de alzheimer y el dolor.
ES2372421T3 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos.
US20060204486A1 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
US20120010288A1 (en) Method for protecting a retinal neuronal cell
ES2673158T3 (es) Nuevo agente terapéutico para la esclerosis lateral amiotrófica (ELA) o enfermedad atribuible a ELA
KR20010071827A (ko) 반점성망막 퇴행에서 신혈관 신생의 예방치료
JP2005533766A (ja) アレルギー反応の治療方法
ES2546672T3 (es) Formulación acuosa estable mejorada de (E)-4-carboxiestiril-4-clorobencilsulfona
ES3006014T3 (en) Use of nalfurafine for the treatment of demyelinating diseases
US20110021618A1 (en) Methods of treating fibrotic disorders
KR100342367B1 (ko) 녹내장치료제및안압강하제
US11622954B2 (en) Estrogen receptor ligands, compositions and methods related thereto
ES2989515T3 (es) Fármaco profiláctico o terapéutico para enfermedades neurodegenerativas
US20040039003A1 (en) Treatment of hepatic cirrhosis
CA2192576A1 (en) Remedy for allergic diseases in the region of the nose
IL93243A (en) Preparations for the prevention of neurodegeneration
JP4695326B2 (ja) 鼻炎用医薬組成物
EP2599480A1 (en) Compounds for the treatment of influenza
JP2009235093A (ja) 鼻炎用医薬組成物
ES2341517B1 (es) Utilizacion de un compuesto inhibidor de la activacion de la enzima erk 1/2 en el tratamiento de enfermedades neurodegenerativas.
AU748754B2 (en) Treatment of hepatic cirrhosis
WO1994003167A1 (fr) Remede contre la cataracte
CA3022900C (en) Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases